DOCSLIB.ORG

EAU-EANM-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer N. Mottet (Chair), R.C.N. van den Bergh, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse © European Association of Urology 2019 TABLE OF CONTENTS PAGE 1. INTRODUCTION 9 1.1 Aims and scope 9 1.2 Panel composition 9 1.2.1 Acknowledgement 9 1.3 Available publications 9 1.4 Publication history and summary of changes 9 1.4.1 Publication history 9 1.4.2 Summary of changes 9 2. METHODS 12 2.1 Data identification 12 2.2 Review 13 2.3 Future goals 13 3. EPIDEMIOLOGY AND AETIOLOGY 13 3.1 Epidemiology 13 3.2 Aetiology 14 3.2.1 Family history / genetics 14 3.2.2 Risk factors 14 3.2.2.1 Metabolic syndrome 14 3.2.2.1.1 Diabetes/metformin 14 3.2.2.1.2 Cholesterol/statins 14 3.2.2.1.3 Obesity 14 3.2.2.2 Dietary factors 14 3.2.2.3 Hormonally active medication 15 3.2.2.3.1 5-alpha-reductase inhibitors 15 3.2.2.3.2 Testosterone 15 3.2.2.4 Other potential risk factors 15 3.2.3 Summary of evidence and guidelines for epidemiology and aetiology 16 4. CLASSIFICATION AND STAGING SYSTEMS 16 4.1 Classification 16 4.2 Gleason score and International Society of Urological Pathology 2014 grade 17 4.3 Prognostic relevance of stratification 17 5. DIAGNOSTIC EVALUATION 18 5.1 Screening and early detection 18 5.1.1 Screening 18 5.1.2 Early detection 19 5.1.3 Guidelines for screening and early detection 20 5.2 Clinical diagnosis 20 5.2.1 Digital rectal examination 20 5.2.2 Prostate-specific antigen 20 5.2.2.1 PSA density 20 5.2.2.2 PSA velocity and doubling time 21 5.2.2.3 Free/total PSA ratio 21 5.2.2.4 Additional serum testing 21 5.2.2.5 Urine tests: PCA3 marker/SelectMDX/Mi Prostate score (MiPS)/ExoDX 21 5.2.2.6 Guidelines for risk-assessment of asymptomatic men 22 5.2.3 Baseline biopsy 22 5.2.4 The role of imaging in clinical diagnosis 22 5.2.4.1 Transrectal ultrasound (TRUS) and ultrasound-based techniques 22 5.2.4.2 Multiparametric magnetic resonance imaging (mpMRI) 22 5.2.4.2.1 mpMRI performance in detecting ISUP grade > 2 PCa 22 5.2.4.2.2 mpMRI performance in detecting ISUP grade group 1 PCa 22 5.2.4.2.3 Does MRI-TBx improve the detection of ISUP grade > 2 as compared to systematic biopsy? 23 2 PROSTATE CANCER - UPDATE MARCH 2019 5.2.4.2.4 Does MRI-TBx reduce the detection of ISUP grade 1 PCa as compared to systematic biopsy? 23 5.2.4.2.5 The added value of systematic and targeted biopsy 23 5.2.4.2.6 Number of biopsy procedures potentially avoided in the ‘MR pathway’ 24 5.2.4.2.7 Other considerations 24 5.2.4.2.7.1 mpMRI reproducibility 24 5.2.4.2.7.2 Targeted biopsy accuracy and reproducibility 24 5.2.4.2.7.3 Role of risk-stratification 25 5.2.4.3 Summary of evidence and practical considerations on pre-biopsy mpMRI 25 5.2.4.4 Summary of evidence and guidelines for imaging 25 5.2.5 Repeat biopsy 26 5.2.5.1 Repeat biopsy after previously negative biopsy 26 5.2.5.1.1 Tests to select men for a repeat biopsy 26 5.2.5.2 Saturation biopsy 26 5.2.6 Prostate biopsy procedure 27 5.2.6.1 Sampling sites and number of cores 27 5.2.6.2 Antibiotics prior to biopsy 27 5.2.6.3 Local anaesthesia prior to biopsy 27 5.2.6.4 Complications 27 5.2.6.5 Seminal vesicle biopsy 27 5.2.6.6 Transition zone biopsy 27 5.2.6.7 Fine-needle aspiration biopsy 28 5.2.7 Pathology of prostate needle biopsies 28 5.2.7.1 Processing 28 5.2.7.2 Microscopy and reporting 28 5.2.7.3 Tissue-based prognostic biomarker testing 29 5.2.7.4 Histopathology of radical prostatectomy specimens 29 5.2.7.4.1 Processing of radical prostatectomy specimens 29 5.2.7.4.1.1 Guidelines for processing prostatectomy specimens 29 5.2.7.4.2 Radical prostatectomy specimen report 29 5.2.7.4.3 ISUP grade in prostatectomy specimens 30 5.2.7.4.4 Definition of extraprostatic extension 30 5.2.7.4.5 PCa volume 31 5.2.7.4.6 Surgical margin status 31 5.2.8 Guidelines for the clinical diagnosis of prostate cancer 31 5.3 Diagnosis – Clinical Staging 31 5.3.1 T-staging 31 5.3.1.1 TRUS 31 5.3.1.2 mpMRI 32 5.3.2 N-staging 32 5.3.2.1 Computed tomography (CT) and magnetic resonance imaging 32 5.3.2.2 Choline PET/CT 32 5.3.2.3 Prostate-specific membrane antigen-based PET/CT 32 5.3.3 M-staging 33 5.3.3.1 Bone scan 33 5.3.3.2 Fluoride PET and PET/CT, choline PET/CT and MRI 33 5.3.3.3 Prostate-specific membrane antigen-based PET/CT 33 5.3.4 Summary of evidence and practical considerations on initial N/M staging 34 5.3.5 Guidelines for staging of prostate cancer 34 5.4 Evaluating life expectancy and health status 34 5.4.1 Introduction 34 5.4.2 Life expectancy 34 5.4.3 Health status screening 35 5.4.3.1 Comorbidity 35 5.4.3.2 Nutritional status 35 5.4.3.3 Cognitive function 35 5.4.3.4 Physical function 35 PROSTATE CANCER - UPDATE MARCH 2019 3 5.4.4 Conclusion 36 5.4.5 Guidelines for evaluating health status and life expectancy 38 6. TREATMENT 38 6.1 Treatment modalities 38 6.1.1 Deferred treatment (active surveillance/watchful waiting) 38 6.1.1.1 Definitions 38 6.1.1.2 Active surveillance 39 6.1.1.3 Watchful Waiting 39 6.1.1.3.1 Introduction 39 6.1.1.3.2 Outcome of watchful waiting compared with active treatment 39 6.1.1.4 The ProtecT study 40 6.1.2 Radical prostatectomy 40 6.1.2.1 Surgical techniques 41 6.1.2.1.1 Pelvic lymph node dissection 41 6.1.2.1.2 Sentinel node biopsy analysis 41 6.1.2.1.3 Nerve-sparing surgery 41 6.1.2.1.4 Neoadjuvant androgen deprivation therapy 41 6.1.2.1.5 Lymph-node-positive patients during radical prostatectomy 42 6.1.2.2 Comparing effectiveness of radical prostatectomy vs. other interventions for localised disease 42 6.1.2.2.1 Radical prostatectomy vs. deferred treatment 42 6.1.2.2.2 Radical prostatectomy vs. radiotherapy 42 6.1.2.3 Acute complications of surgery 42 6.1.2.3.1 Early complications of extended lymph node dissection 43 6.1.3 Radiotherapy 43 6.1.3.1 External Beam Radiation Therapy: 43 6.1.3.1.1 Technical aspects: intensity-modulated external-beam radiotherapy and volumetric arc external-beam radiotherapy 43 6.1.3.1.2 Dose escalation 43 6.1.3.1.3 Hypofractionation 44 6.1.3.1.4 Neoadjuvant or adjuvant hormone therapy plus radiotherapy 46 6.1.3.1.5 Combined dose-escalated radiotherapy and androgen- deprivation therapy 47 6.1.3.2 Proton beam therapy 48 6.1.3.3 Brachytherapy 48 6.1.3.3.1 Low-dose rate brachytherapy 48 6.1.3.3.2 High-dose rate brachytherapy 48 6.1.3.4 Acute side-effects of external beam radiotherapy and brachytherapy 49 6.1.4 Hormonal therapy 49 6.1.4.1 Introduction 49 6.1.4.1.1 Different types of hormonal therapy 49 6.1.4.1.1.1 Testosterone-lowering therapy (castration) 49 6.1.4.1.1.1.1 Castration level 49 6.1.4.1.1.1.2 Bilateral orchiectomy 49 6.1.4.1.1.2 Oestrogens 49 6.1.4.1.1.3 Luteinising-hormone-releasing hormone agonists 50 6.1.4.1.1.4 Luteinising-hormone-releasing hormone antagonists 50 6.1.4.1.1.5 Anti-androgens 50 6.1.4.1.1.5.1 Steroidal anti-androgens 50 6.1.4.1.1.5.1.1 Cyproterone acetate 50 6.1.4.1.1.5.2 Non-steroidal anti-androgens 50 6.1.4.1.1.5.2.1 Nilutamide 51 6.1.4.1.1.5.2.2 Flutamide 51 6.1.4.1.1.5.2.3 Bicalutamide 51 4 PROSTATE CANCER - UPDATE MARCH 2019 6.1.4.1.1.6 New compounds 51 6.1.4.1.1.6.1 Abiraterone acetate 51 6.1.4.1.1.6.2 Enzalutamide 51 6.1.4.1.1.6.3 Apalutamide 51 6.1.5 Investigational therapies 51 6.1.5.1 Background 51 6.1.5.2 Cryotherapy 51 6.1.5.3 High-intensity focused ultrasound 52 6.1.5.4 Focal therapy 52 6.1.6 General guidelines for active treatment 53 6.1.7 Discussing treatment options 53 6.2 Treatment by disease stages 53 6.2.1 Treatment of low-risk disease 53 6.2.1.1 Active surveillance 53 6.2.1.1.1 Selection criteria for active survillance based on clinical and pathological variables 53 6.2.1.1.2 Biological markers 53 6.2.1.1.3 Imaging for treatment selection 54 6.2.1.1.3.1 mpMRI in men eligible for active surveillance based on systematic biopsy findings only 54 6.2.1.1.3.1.1 Reduction of systematic biopsies in MRI-negative men on active surveillance.
Recommended publications
  • Oral Presentations September 23Rd - Rooms 1,2 and 3

    Oral Presentations September 23Rd - Rooms 1,2 and 3

    Oral Presentations September 23rd - Rooms 1,2 and 3 Presentation Date Abstract Authors Presenter´s name - Theme Title Code indicated by the author 18498 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of PERFORMANCE OF AN IMMUNOASSAY Eric Franssen; Milly Attema-de abuse METHOD FOR GAMMA-HYDROXYBUTYRIC Jonge ACID (GHB) IN PATIENTS PRESENTED AT THE EMERGENCY DEPARTMENT, A PROSPECTIVE STUDY 18499 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of DO WE NEED POINT-OF-CARE TESTING OF Milly Attema-de Jonge; Eric abuse GAMMA-HYDROXYBUTYRIC ACID (GHB) AT Fransse THE EMERGENCY DEPARTMENT? September 23 18730 Lilian H.J. Richter; Julia Menges; Lea Wagmann Clinical Toxicology/drugs of NEW PSYCHOACTIVE SUBSTANCES: Lea Wagmann; Simon D. Brandt; abuse METABOLIC FATE, ISOZYME-MAPPING, 13:30 - 14:45 Folker Westphal; Veit Flockerzi; AND PLASMA PROTEIN BINDING OF 5-APB- ROOM 1 Markus R. Meyer NBOME, 2C-B-FLY-NB2ETO5CL, AND 2C-B- FLY-NBOME 18985 Annelies Cannaert; Marie Annelies Cannaert Clinical Toxicology/drugs of HIDE AND SEEK: OVERCOMING THE Deventer; Melissa Fogarty; abuse MASKING EFFECT OF OPIOID Amanda L.A. Mohr; Christophe P. ANTAGONISTS IN ACTIVITY-BASED Stove SCREENING TESTS 18740 Souleiman El Balkhi ; Roland Souleiman El Balkhi Clinical Toxicology/drugs of METABOLIC INTERACTIONS BETWEEN Lawson; Franck Saint-Marcoux abuse OXYCODONE, BENZODIAZEPINES OR DESIGNER BENZODIAZEPINES PLAY AN IMPORTANT ROLE IN OXYCODONE INTOXICATIONS 19050 Brenda de Winter F de Velde; MN Brenda de Winter Anti-infective drugs POPULATION
  • Formulary Adherence Checklist

    Formulary Adherence Checklist

    NICE Technology Appraisals About Medicines: Formulary Adherence Checklist This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS. Last updated 18-Jun-19 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as indicated by (TA) Release NICE Adherence of local formulary to NICE Titles are hyperlinks to Yes N/A Date of local Date of local Time to full guidance (mark 'x' if (mark 'x' if decision decision implement applicable) applicable) Due (90 days) Made (days) 2018-19 TA517 Avelumab for Avelumab for treating metastatic Merkel cell carcinoma. 1 treating metastatic 11/04/2018 Evidence-based recommendations on avelumab (Bavencio) for treating metastatic X 10/07/2018 17/12/2018 250 Merkel cell carcinoma (secondary) Merkel cell carcinoma in adults. TA518 Tocilizumab for Tocilizumab for treating giant cell arteritis. 1 treating giant cell 18/04/2018 Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell X 17/07/2018 16/07/2018 89 arteritis arteritis in adults. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after TA519 Pembrolizumab platinum-containing chemotherapy. for treating locally Evidence-based recommendations on pembrolizumab (Keytruda) for previously advanced or metastatic treated locally advanced or metastatic urothelial carcinoma in adults. 1 urothelial carcinoma 25/04/2018 X 24/07/2018 04/05/2018 9 after platinum- containing chemotherapy TA520 - Atezolizumab Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced for treating locally or metastatic non-small-cell lung cancer after chemotherapy in adults.
  • Anthem Blue Cross Drug Formulary

    Anthem Blue Cross Drug Formulary

    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
  • TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study

    TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study

    TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study Protocol 253PC101 Protocol Amendment #4 Dated 30May2019 IN CASE OF EMERGENCY Table 1: Emergency Contact Information Role in Study Name Address and Telephone number Primary Medical Monitor James Freddo, MD 4350 La Jolla Village Drive, Suite 800 San Diego, CA 92122 Mobile Phone: 1.858.472.2330 Facsimile: 1.858.550.0786 Email: [email protected] Secondary Medical Monitor Charles Theuer, MD, PhD 4350 La Jolla Village Drive, Suite 800 San Diego, CA 92122 Office: 1.858.550.0780 x233 Mobile Phone: 1.858.344.9400 Email: [email protected] Confidential Page 2 of 102 TRACON Pharmaceuticals, Inc. IND 132664 5.3.3.2 Clinical Study Protocol 253PC101 Protocol Amendment #4 Dated 30May2019 1. SYNOPSIS Name of Sponsor/Company: TRACON Pharmaceuticals, Inc. Name of Investigational Product: TRC253 Name of Active Ingredient: TRC253-HCl Title of Study: AN OPEN-LABEL PHASE 1/2A STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY EFFICACY OF TRC253, AN ANDROGEN RECEPTOR ANTAGONIST, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Study center(s): 6 centers in Part 1, and approximately 20 centers in Part 2, in the United States Studied period: Phase of development: 1/2A Date first patient enrolled: May 2017 Date of determination of recommended phase 2 dose (RP2D): July 2018 Estimated date last patient enrolled: April 2021 Estimated date last patient completed: October 2021 Rationale: TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR.
  • Here Is a Range of New Agents, Molecular Markers Ethics and Human Rights

    Here Is a Range of New Agents, Molecular Markers Ethics and Human Rights

    European Urology Today First Edition EUT Congress News 32nd33rd AnnualAnnual CongressCongress ofof thethe EuropeanEuropean AssociationAssociation ofof UrologyUrology Saturday, 2517 MarchMarch 20182017 Copenhagen,London, 24-2816-20 March 20182017 Meeting the challenges in urogenital diseases EU Health Commissioner Andriukaitis urges stronger collaboration By Joel Vega and Erika de Groot currently numbers 29 active units in 11 EU member Dr. Deepansh Dalela (US) received the Hans EAU Ernest Desnos Prize for his contributions to states. Marberger Award for the best European paper urological history, while Hashim Ahmed (GB) To the rhythmic, high energy beat of the published on minimally invasive surgery in was awarded the EAU Prostate Cancer Research synchronized, four-man Copenhagen Drummers Chapple also highlighted the crucial role of the EU in urology. Prof. Sergio Musitelli (IT) received the first Award. band, the 33rd Annual EAU Congress opened creating the ERNs which he said will lead to better data yesterday with European Commissioner for Health collection and mutual collaboration among European and Food Safety, Prof. Vytenis Andriukaitis (LT) scientists and clinical professionals. “To ensure the urging the audience to collaborate in the European sustainability of this project we need to form Reference Networks (ERNs). partnerships and work on common goals,” he said. “This flagship project reflects not only the need The Opening Ceremony traditionally highlights the to further strengthen our collaboration, but also EAU’s honorary members and awardees. Chapple the fact that we can and have achieved a lot if we conferred the title of Honorary Members to Gunnar put together our resources, knowledge and Aus (SE), Patrick Coloby (FR), Mani Menon (US) and commitment,” said Andriukaitis.
  • Fluoroquinolones-Associated Disability: It Is Not All in Your Head

    Fluoroquinolones-Associated Disability: It Is Not All in Your Head

    Review Fluoroquinolones-Associated Disability: It Is Not All in Your Head Maya Z. Freeman , Deanna N. Cannizzaro, Lydia F. Naughton and Cecilia Bove * Department of Biology, Bucknell University, Lewisburg, PA 17837, USA; [email protected] (M.Z.F.); [email protected] (D.N.C.); [email protected] (L.F.N.) * Correspondence: [email protected] Abstract: Fluoroquinolones (FQs) are a broad class of antibiotics typically prescribed for bacterial infections, including infections for which their use is discouraged. The FDA has proposed the existence of a permanent disability (Fluoroquinolone Associated Disability; FQAD), which is yet to be formally recognized. Previous studies suggest that FQs act as selective GABAA receptor inhibitors, preventing the binding of GABA in the central nervous system. GABA is a key regulator of the vagus nerve, involved in the control of gastrointestinal (GI) function. Indeed, GABA is released from the Nucleus of the Tractus Solitarius (NTS) to the Dorsal Motor Nucleus of the vagus (DMV) to tonically regulate vagal activity. The purpose of this review is to summarize the current knowledge on FQs in the context of the vagus nerve and examine how these drugs could lead to dysregulated signaling to the GI tract. Since there is sufficient evidence to suggest that GABA transmission is hindered by FQs, it is reasonable to postulate that the vagal circuit could be compromised at the NTS-DMV synapse after FQ use, possibly leading to the development of permanent GI disorders in FQAD. Keywords: fluoroquinolones; fluoroquinolones-associated-disability; vagus; gastrointestinal; digestion; DMV; NTS; FQAD Citation: Freeman, M.Z.; Cannizzaro, D.N.; Naughton, L.F.; Bove, C.
  • Penicillin Allergy Guidance Document

    Penicillin Allergy Guidance Document

    Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment.
  • Drug-Facilitated Sexual Assault Panel, Blood

    Drug-Facilitated Sexual Assault Panel, Blood

    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
  • Single Technology Appraisal Padeliporfin for Treating Localised

    Single Technology Appraisal Padeliporfin for Treating Localised

    Single Technology Appraisal Padeliporfin for treating localised prostate cancer [ID866] Committee Papers © National Institute for Health and Care Excellence 2018. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SINGLE TECHNOLOGY APPRAISAL Padeliporfin for treating localised prostate cancer [ID866] Contents: 1. Pre-Meeting Briefing 2. Final Scope and Final Matrix of Consultees and Commentators 3. Company submission from Steba Biotech 4. Clarification letters NICE request to the company for clarification on their submission Company response to NICE’s request for clarification 5. Patient group, professional group and NHS organisation submission from: British Association of Urological Surgeons 6. Expert statements from: Caroline Moore, clinical expert, nominated by British Association of Urological Surgeons Mark Emberton – clinical expert, nominated by Steba Biotech 7. Evidence Review Group report prepared by Aberdeen HTA Group 8. Evidence Review Group report – addendum Evidence Review Group report – factual accuracy check – the company stated that they did not identify any factual inaccuracies in the ERG report Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted. © National Institute for Health and Care Excellence 2018. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. Pre-meeting briefing Padeliporfin for treating localised prostate cancer [ID866] This slide set is the pre-meeting briefing for this appraisal.
  • To Hold (Enteral Feeding) Or Not to Hold: That IS the Question; a Commentary and Tutorial

    To Hold (Enteral Feeding) Or Not to Hold: That IS the Question; a Commentary and Tutorial

    NUTRITIONINFLAMMATORY ISSUES BOWEL IN GASTROENTEROLOGY, DISEASE: A PRACTICAL SERIES APPROACH, #101 SERIES #73 Carol Rees Parrish, M.S., R.D., Series Editor To Hold (Enteral Feeding) or Not to Hold: That IS the Question; A Commentary and Tutorial by Lingtak-Neander Chan, PharmD, BCNSP Enteral nutrition may interfere with drug absorption and lead to therapeutic failure. The best management plan to minimize this interaction remains controversial. One of the solutions to this clinical issue involves withholding enteral feeding for a period of time in order to minimize the potential risk factors that interfere with oral bioavailability of drugs. Although data from the literature suggest that this approach is associated with limited success in some cases, the length of time enteral feeding was held varied among studies. This article serves as a tutorial guide to help clinicians determine when these concerns may be more clinically significant and what actions can be considered to optimize patient outcomes. INTRODUCTION hould enteral nutrition (EN) be withheld before the new feeding regimen by the patient may become this medication is administered? What do we an issue. From the pharmacotherapeutic perspective, actually accomplish by holding EN? How long there are concerns that the absorption pattern and Sshould EN be withheld? Should EN be stopped both bioavailability of drug are altered by EN, thus affecting before and after drug administration? These are some of the safety and efficacy profiles of medications. The aim the questions that many clinicians have been wondering of this article is to discuss when these concerns are about for a long time. Often times, the responses can clinically significant and what actions could be taken be quite different, and even conflicting, depending to optimize patient care.
  • Severe Confusion Possibly Caused by Levofloxacin 5-311 Teodora C

    Severe Confusion Possibly Caused by Levofloxacin 5-311 Teodora C

    Severe Confusion Possibly Caused by levofloxacin 5-311 Teodora C. Stefan, PharmD Candidate1, Kimberly A. Couch, PharmD, MA, FIDSA, FASHP1,2 1University of Maryland Eastern Shore School of Pharmacy and Health Professions 2CompleteRx Abstract Discussion Results Levofloxacin is a third generation fluoroquinolone antibiotic which is generally well • The major reported adverse effects of fluoroquinolones are tolerated, and has a very low rate of clinically relevant neurological adverse events (0.2- • 91 yo male with CAP gastrointestinal (3-17%) and CNS (0.9-11%) disturbances4. 1.1%)1. The more common central nervous system(CNS) adverse effects are • PMH: HTN, dyslipidemia, hypothyroidism, BPH • Predisposing factors for CNS related adverse events include5 headache, dizziness, restlessness, tremor, insomnia, anxiety and depression. Delirium • CrCl = 28 mL/min • elderly age and hallucinations have been reported with fluoroquinolones as well as seizures. This • male gender case report describes changes in mental status experienced by an elderly patient who was receiving levofloxacin for presumed pneumonia. This 91 year old male was HD#1 HD#2 HD#3 HD#4 HD#5 HD#6 • diabetes mellitus admitted to the hospital with fever, cough, and rigors and started empirically on • Hypoxemia • any neurological illness levofloxacin for community acquired bacterial pneumonia. The patient became severely confused, agitated and combative approximately 12 hours after the first dose of • severe atherosclerosis levofloxacin. The patient’s oxygen saturations were within normal limits, electrolytes within normal limits, and no other cause for his change in mental status was apparent. Conclusions The patient received 2 doses of levofloxacin 750 mg administered 48 hours apart which was appropriate for his renal function.
  • NSCLC Therapeutics in Asia-Pacific Markets to 2019 Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

    NSCLC Therapeutics in Asia-Pacific Markets to 2019 Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

    NSCLC Therapeutics in Asia-Pacific Markets to 2019 Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool GBI Research Report Guidance GBI Research Report Guidance Chapter two provides an overview of the disease, its symptoms, etiology, pathophysiology, diagnosis, classification, epidemiology, prognosis, staging and treatment options. Chapter three provides a detailed profiling and comparative heat map analysis in terms of safety and efficacy for currently marketed products in the NSCLC market. Chapter four presents a detailed pipeline analysis for the disease, including individual product profiles, a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the NSCLC developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes, by participant numbers. Chapter five provides market forecasts for countries across the globe, with special attention given to the APAC countries: India, Australia, China and Japan. The multiple scenario forecasts take into account a range of factors that are likely to vary and provide a clear perspective on the level of the potential degree of variance in the market sizes. Chapter six covers the major deals that have taken place in the disease market in recent years. Coverage includes co-development deals and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.